Melanoma Research Review, Issue 42

In this issue:

Adjuvant pembrolizumab vs placebo in resected stage III melanoma
Topical calcineurin inhibitor use and risk of cancer
ICB-induced autoimmunity and outcomes in metastatic melanoma and distinct T-cell expression profiles
uPAR+ EVs as a biomarker of resistance to ICBs in metastatic melanoma patients
Safety and efficacy of ICBs in patients with melanoma and preexisting AID
Lymphodepletion + adoptive cell transfer of TILs +/- dendritic cell vaccination in metastatic melanoma
Predicting anti-PD-1 responders in malignant melanoma from the frequency of S100A9+ monocytes in the blood
ADI-PEG20 + cisplatin in patients with pretreated metastatic melanoma
Neoadjuvant ipilimumab + nivolumab in synchronous clinical stage III melanoma
irAEs with adjuvant ipilimumab in melanoma: use of immunosuppressants and association with outcome

Please login below to download this issue (PDF)

Subscribe